Stockscreener 앱 받기
5.52
39.75%
1.57
전일 마감가:
$3.95
열려 있는:
$4.7
하루 거래량:
176.86M
Relative Volume:
11.50
시가총액:
$5.44B
수익:
$1.31M
순이익/손실:
$-597.65M
주가수익비율:
-5.6907
EPS:
-0.97
순현금흐름:
$-425.62M
1주 성능:
+136.91%
1개월 성능:
+155.56%
6개월 성능:
+100.73%
1년 성능:
+81.58%
1일 변동 폭
$4.38
$5.58
1주일 범위
$2.284
$5.58
52주 변동 폭
$1.83
$5.58
Immunitybio Inc Stock (IBRX) Company Profile
명칭
Immunitybio Inc
전화
(844) 696-5235
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
IBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
5.52 | 3.89B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 개시 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | BTIG Research | Buy |
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline - TechStock²
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next - TechStock²
ImmunityBio Shares Soar On 700 Percent Revenue Surge - Evrim Ağacı
Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL - The American Journal of Managed Care® (AJMC®)
ImmunityBio rises after Saudi approval of Anktiva - MSN
ImmunityBio (IBRX) Stock: This Biotech Doubled in Three Weeks on Cancer Drug Success - CoinCentral
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update - TechStock²
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next - TechStock²
ImmunityBio’s bladder cancer trial enrollment at 85%, BLA filing planned By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results - Finviz
ImmunityBio Stock Pre-Market (+9.4%): Positive Bladder Cancer Trial Update Accelerates FDA Plan - Trefis
JPM movers: ImmunityBio rises to the top - BioCentury
ImmunityBio’s 700% Revenue Surge Validates Citadel’s Forecast: NASDAQ: IBRX - filmogaz.com
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) (NASDAQ:IBRX) - Seeking Alpha
Immunitybio’s CAR-NK shows complete responses in Waldenström’s - BioWorld MedTech
ImmunityBio Moves CAR-NK Ahead After Showing Durable Efficacy - Citeline News & Insights
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year - Yahoo Finance
Stock Movers: ASML, ImmunityBio, Constellation - Bloomberg.com
IBRXImmunityBio Inc Stock Price and Quote - Finviz
There's Reason For Concern Over ImmunityBio, Inc.'s (NASDAQ:IBRX) Massive 83% Price Jump - 富途牛牛
Key facts: ImmunityBio shares up 24% on trial enrollment news; Anktiva shows 84% success - TradingView — Track All Markets
ImmunityBio reports early signals from off-the-shelf cell therapy in lymphoma - FirstWord Pharma
Why ImmunityBio Stock Is Skyrocketing Again Today - Nasdaq
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view - TechStock²
ImmunityBio (IBRX) extends gains to 10th day on 700% Anktiva sales jump; time to book profits? - MSN
ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? - Finviz
Nogapendekin Alfa Inbakicept Plus BCG Yields Significant DOR in BCG-Naive NMIBC - OncLive
ImmunityBio's cell therapy posts encouraging early results in rare form of lymphoma - Endpoints News
ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So - Benzinga
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line - TechStock²
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma - Proactive Investors
Looking For A Short Squeeze? 10 Stocks Ready To Rocket - Benzinga
Immunitybio stock hits 52-week high at 4.68 USD By Investing.com - Investing.com Australia
Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - Benzinga
This Biotech Stock Is Up More Than 100% This Year. Why It’s Soaring Again Today. - Barron's
Stock Movers: ImmunityBio, Micron, JB Hunt - Bloomberg.com
Immunitybio stock hits 52-week high at 4.68 USD - Investing.com
ImmunityBio touts 15-month complete response in CAR-NK trial - Fierce Biotech
ImmunityBio Stock Surges 22% as Revenue and Trials Impress Investors - timothysykes.com
ImmunityBio Stock (IBRX) Opinions on 700% Revenue Growth - Quiver Quantitative
IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment - Stocktwits
These Stocks Are Today’s Movers: Micron, Sandisk, AST SpaceMobile, ImmunityBio, HP Inc., Novo Nordisk, and More - Barron's
Flurry of positive announcements make ImmunityBio the next short squeeze target for retail traders - Sherwood News
ImmunityBio (IBRX) Surpasses Enrollment Expectations in QUILT-2.005 Trial, Shares Up 25% - Intellectia AI
ImmunityBio (IBRX) Stock Surges 30% on 700% Revenue Growth - Blockonomi
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG - Investing News Network
ImmunityBio’s bladder cancer trial enrollment at 85%, BLA filing planned - Investing.com India
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma - Investing News Network
ImmunityBio rises on promising early cancer trial data - TradingView — Track All Markets
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more - CNBC
ImmunityBio announces durable complete response of 15 months with a chemotherapy-free CD19 CAR-NK cell therapy in Waldenstrom lymphoma - marketscreener.com
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):